Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of GS-5806 in HCT recipients with RSV upper respiratory tract infection
2014-002474-36Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing GS-5806 with Placebo (2 arms). Primary endpoint: Time-weighted average change in nasal RSV viral load from baseline to Day 9. Started Sep 2014; status: completed.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2014-002474-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002474-36.